Comparative Effectiveness of Venetoclax Combinations Vs Other Therapies Among Patients with Newly Diagnosed Acute Myeloid Leukemia: Results from the AML Real World Evidence (ARC) Initiative

Introduction: Venetoclax (VEN) is a BCL-2 inhibitor FDA approved in combination with azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC) for newly diagnosed (ND) acute myeloid leukemia (AML) in adults aged ≥75 or those with comorbidities precluding intensive chemotherapy. We explored...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2021-11, Vol.138 (Supplement 1), p.2328-2328
Hauptverfasser:	Garcia, Jacqueline S., Wolach, Ofir, Vachhani, Pankit, Zeidner, Joshua F., Talati, Chetasi, Pollyea, Daniel A., Lai, Catherine, Moshe, Yakir, Abedin, Sameem, Lavie, David, Zuckerman, Tsila, Xavier, Marin, Lee, Sangmin, Edwards, Wesleigh, Chen, Evan, Bui, Cat N., Svensson, Anders, Burne, Rebecca, Kye, Steve, Maitland, Jessica, Ma, Esprit, Montez, Melissa, Grunspan, Moshe, Goldberg, Aaron D
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Introduction: Venetoclax (VEN) is a BCL-2 inhibitor FDA approved in combination with azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC) for newly diagnosed (ND) acute myeloid leukemia (AML) in adults aged ≥75 or those with comorbidities precluding intensive chemotherapy. We explored real-world practices and clinical outcomes of patients (pts) treated with VEN-based vs. non-VEN-based regimens in the AML Real world evidenCe (ARC) Initiative. Methods: This multicenter chart review study includes adult pts with ND AML treated with VEN (VEN cohort) after 11 April 2016 matched to pts with non-VEN-based regimens (control cohort) after 15 May 2015 from 10 academic sites in the US and 4 in Israel. Pts were randomly selected and matched on age (
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood-2021-151285